Cardiovascular disease (CVD) is the leading cause of morbidity, mortality and disability globally imposing a significant burden on individuals, families, and healthcare systems1. Each year in Ireland, over 4000 deaths are attributed to ischaemic heart disease.
The growing population of those living with chronic CVD, heart failure and valvular heart disease are at a higher risk of secondary events, therefore it is essential that these patients receive effective, evidence-based secondary prevention, leading to optimization of cardiovascular health, improved functional capacity and enhanced quality of life.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
